Treatment strategies for skeletal complications of cancer

Cancer Biology and Therapy

Volumn 5, Issue 9, 2006, Pages 1074-1077

  Berenson, James R ^a,c   Rajdev, Lakshmi ^b   Broder, Michael ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Bisphosphonates; Bone; Metastasis; Therapeutics

Indexed keywords

ALENDRONIC ACID; AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE; CLODRONIC ACID; ETIDRONIC ACID; EXEMESTANE; IBANDRONIC ACID; LETROZOLE; MEGESTROL ACETATE; PAMIDRONIC ACID; RADIOPHARMACEUTICAL AGENT; RISEDRONIC ACID; SAMARIUM 153; SODIUM DIHYDROGEN PHOSPHATE; STRONTIUM CHLORIDE; ZOLEDRONIC ACID;

APOPTOSIS; ARTHRALGIA; ASEPTIC NECROSIS; AVASCULAR NECROSIS; BONE ATROPHY; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BONE REMODELING; BONE TURNOVER; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FEVER; FLU LIKE SYNDROME; FRACTURE; HUMAN; HYPERCALCEMIA; KIDNEY DYSFUNCTION; KYPHOPLASTY; MYALGIA; OSTEOCLAST; OSTEOLYSIS; PAIN; PERCUTANEOUS VERTEBROPLASTY; QUALITY OF LIFE; REVIEW; SPINAL CORD COMPRESSION;

EID: 33751111432     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.9.3305     Document Type: Review

References (29)

1. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005; 12:549-83.
2. Raje N, Anderson K. Introduction: the evolving role of bisphosphonate therapy in multiple myeloma. Blood 2000; 96:381-3.
3. Coleman RE. Bisphosphonates: clinical experience. Oncologist 2004; 9:14-27.
4. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4:30-4.
5. Falkmer U, Järhult J, Wersäll P, Cavallin-Stahl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003; 42:620-33.
6. Frassica DA. General principles of external beam radiation therapy for skeletal metastases. Clin Orthop Relat Res 2003; 415:S158-64.
7. Smith H, Navani A, Fishman SM. Radiopharmaceuticals for palliation of painful osseous metastases. Am J Hosp Palliat Care 2004; 21:303-13.
8. Katzer A, Meenen NM, Grabbe F, Rueger JM. Surgery of skeletal metastases. Arch Orthop Trauma Surg 2002; 122:251-8.
9. Fourney DR, Schomer DF, Nader R, Chlan-Fourney J, Suki D, Ahrar K, Rhines LD, Gokaslan ZL. Percutaneous vertebroplasty and kyphoplasty for painful vertebral body fractures in cancer patients. J Neurosurg Spine 2003; 98:21-30.
10. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27:165-76.
11. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000; 289:1508-14.
12. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003; 5:65-74.
13. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-430.
14. Van Breukelen FJ, Bijvoet OL, van Oosterom AT. Inhibition of osteolytic bone lesion by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate. Lancet 1979; 14:803-5.
15. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM.Delay in progression of bone metastases treated with intravenous pamidronate: results from a multicentre randomised controlled trial. J Clin Oncol 1996; 14:2552-9.
16. van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, Hermans J, Kroon HM, Harinck HI, Vermey P, Elte JW, Neijt JP, Beex LV, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. Lancet 1987; ii:983-5.
17. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I, for the Finnish Leukaemia Group. Randomised, placebo-controlled multicentre multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340:1049-52.
18. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double blind controlled trial of clodronate in patients with bone metastases from breast cancer: J Clin Oncol 1993; 11:59-65.
19. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335:1785-91.
20. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, Kilany S. Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomized prospective double blind placebo controlled trial. Acta Oncologica 1996; 35:73-4.
21. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334:488-93.
22. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ. Pamidronate reduces skeletal morbidity in women with advance breast cancer and lytic bone lesions: a randomised, placebo controlled trial. J Clin Oncol 1999; 17:846-54.
23. Body JJ, Lichinitser MR, Diehl IE, et al. Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone. Proc Am Soc Clin Oncol 1999; 18:575a.
24. McCloskey EV, Maclennan ICM, Drayson M, et al. A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol Haematol 1998; 100:317-25.
25. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M; Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96:879-82.
26. Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100:2613-21.
27. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10:52-62.
28. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115-7.
29. Zometa (zoledronic acid) [prescribing information]. Novartis Pharmaceuticals Corporation; East Hanover, NJ: 2004.